Rilemo’s go-to-market strategy is built as a phased market-entry model, starting from selected hospital environments and expanding progressively into broader care settings over time.
<aside> <img src="/icons/first-aid_blue.svg" alt="/icons/first-aid_blue.svg" width="40px" />
The company will initially focus on hospital departments managing acute neurological patients, particularly emergency rooms, neurosurgery departments, and intensive care units, where the need for rapid bedside brain imaging is most immediate and the clinical value proposition is strongest. This first commercial entry point is aligned with the current regulatory pathway and with the need to establish adoption in settings where clinical innovation is validated first.
</aside>
Before full commercialization, Rilemo is already developing relationships with research centers, IRCCS institutions, and clinicians through ongoing collaborations and clinical activities. These interactions are expected to strengthen scientific credibility, increase product awareness, and identify high-potential reference sites ahead of certification. Where feasible and compliant with local requirements, selected centers may also engage with the technology through research-oriented protocols, helping shorten the conversion cycle once certification is achieved.
Following certification, Rilemo expects to convert these pre-developed relationships into its first commercial accounts, starting from a limited number of highly innovative hospital centers in Europe. The initial objective is not broad market coverage, but the activation of selected early adopters that can serve as reference accounts, validation partners, and multipliers for subsequent expansion.
Rilemo’s beachhead market consists of hospital departments treating acute neurological patients, where fast point-of-care brain imaging can support time-sensitive assessment and decision-making close to the patient.
In this first phase, the device is positioned as a rapid point-of-care imaging tool that complements CT and MRI by enabling immediate bedside assessment and repeat acquisitions over time when needed. This positioning is particularly relevant in settings where patient transport may be complex, imaging access may not be immediate, or more frequent reassessment may provide additional clinical value.
The initial target departments are therefore:
This hospital-first entry is expected to create the foundation for future expansion into adjacent settings, including ambulances, long-term care environments, and decentralized healthcare infrastructures, once the company has established stronger clinical adoption and broader regulatory and commercial maturity.
In parallel with its commercial go-to-market, Rilemo runs a structured research collaboration programme with universities, IRCCS institutions, and independent clinical research centres. Devices are placed at partner institutions at a contribution-based fee, set at near cost-recovery level by design, to maximise engagement and ensure partners have strong incentive to participate actively. In return, Rilemo gains structured access to real-world clinical data that feeds directly into product development and AI model refinement, while building a network of clinical champions and key opinion leaders ahead of full commercialisation. These collaborations are reflected in the Financial Plan as research contributions.
Market access will begin through three primary channels: